Powered by Google

2014-14: A Two-Year, Randomized, Double-Masked, Multicenter, Two-Arm Study Comparing the Efficacy and Safety of RTH258 6 mg Versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration

Medical retina
Drug research
Contract Research
Inclusion open since 27-11-2015

Age-related macular degeneration (AMD) is the leading cause of severe vision loss affecting 10-13% of individuals over the age of 65 in western countries. The clinical subtype, neovascular AMD, is characterized by growth of abnormal blood vessels which increases the likelihood of leakage and retinal damage. Without treatment, moste affected eyes will have poor central vision within 12 months. Although anti-vascular endothelial growth factors improve visual outcome, there still remains a need for treatments and regimens which offer a reduced frequency of injections.

By visiting eyehospital.nl you are accepting the use of cookies. Read more about cookies.

Hide this message